Boehringer Ingelheim has received conditional approval from China's National Medical Products Administration (NMPA) for zongertinib (Hernexeos) as a first-line monotherapy in adults with unresectable, locally advanced or metastatic HER2-mutant NSCLC, marking the first targeted oral therapy cleared for this population at initial diagnosis in China. The decision, based on a 75.7% objective response rate in treatment-naïve patients from the Phase Ib Beamion LUNG-1 trial, follows the drug's US FDA accelerated approval in February 2026 and extends zongertinib's regulatory footprint to the US, China, Hong Kong, and Japan.
Beamion LUNG-1 is an open-label Phase Ib dose-escalation and expansion study evaluating zongertinib across HER2-aberrant solid tumors. The China NMPA approval drew on data from a cohort of 74 treatment-naïve patients with HER2 (ERBB2) tyrosine kinase domain activating mutations, in which zongertinib produced an ORR of 75.7%, comprising a 10.8% complete response rate and a 64.9% partial response rate. The median duration of response was 15.2 months. These data were presented at the European Lung Cancer Congress 2026 and published in the New England Journal of Medicine. In a pooled safety population of 177 patients with HER2-mutant NSCLC enrolled in Beamion LUNG-1, treatment-related adverse events were predominantly low-grade; dose reductions occurred in 9% of patients and dose discontinuations in 6%. The conditional approval requires confirmation of clinical benefit from an ongoing trial before full approval is granted.
Competitive context
Zongertinib is an irreversible TKI that selectively inhibits HER2 while sparing wild-type EGFR, a design intended to reduce the diarrhea and rash associated with pan-HER inhibitors. The primary approved alternative in HER2-mutant NSCLC is AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), an intravenous antibody-drug conjugate approved by the FDA in 2022 for previously treated patients; cross-trial comparisons are limited, but zongertinib's 75.7% first-line ORR compares favorably in absolute terms to the roughly 37–38% ORR reported for trastuzumab deruxtecan in the second-line DESTINY-Lung02 setting, with the caveat that patient populations and trial designs differ materially. Bayer's Hyrnuo (sevabertinib), a reversible oral HER2 TKI, received FDA accelerated approval in November 2025 for previously treated patients, adding a second oral option in the post-platinum setting. The confirmatory Phase III Beamion LUNG-2 trial, evaluating zongertinib as initial treatment in HER2 TKD-mutant advanced NSCLC, is ongoing and will provide the randomized data needed to support full approval in both China and the US.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article